BCL2 and cancer: Since BCL-XL was suggested as a factor of resistance to direct BAX activation in our panel of cancer cell lines, we examined whether Navitoclax, a clinical BCL-XL/BCL-2 inhibitor, would be able to promote cytotoxicity against the same panel of cancer cell lines.